Biosensors to aquire birfurcation lesion DES for $5.7M

Kaitlyn Dmyterko | | Health Imaging | Enterprise Imaging
Biosensors International has acquired assets of Devax, including the Axxess drug-eluting stent (DES) system, for a total cost consideration of $5.7 million.

The Axxess DES system is indicated for the treatment of complex types of coronary artery disease (CAD), such as those where coronary bifurcation lesions occur between two vessels, which occurs in an estimated 15 percent to 25 percent of the patients undergoing PCI.

Biosensors said that the cost consideration of $5.7 million is from an existing cash resource and internally-generated funds. The acquisition will not have a material impact on the consolidated earnings per share or net tangible assets of the company’s financial year, ending March 31.

The Axxess DES system is a nitinol stent that is coated with Biolimus A9, a polymer licensed from Biosensors and used in Biosensors BioMatrix DES portfolio. The Axxess DES received CE mark in August 2010 after results of the DIVERGE trial, which studied the safety and efficacy of the device to treat coronary bifurcation lesions, showed low rates of major adverse cardiovascular events (MACE) and stent thrombosis.

Kaitlyn Dmyterko

Related Content

Less than half of incidental interstitial lung abnormalities on CT exams are reported
Are providers too trusting of AI's advice?
Pairing an alert system with CAD software halves time-to-treatment for pneumothorax
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Rads are more accurate when they have access to patients' self-reported symptoms
AI-based software improves follow-up imaging adherence by 74%

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.